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Abstract
Receptor-tyrosine-kinase-like orphan receptor 1 (ROR1) is expressed during embryogenesis and by certain leukemias, but
not by normal adult tissues. Here we show that the neoplastic cells of many human breast cancers express the ROR1 protein
and high-level expression of ROR1 in breast adenocarcinoma was associated with aggressive disease. Silencing expression
of ROR1 in human breast cancer cell lines found to express this protein impaired their growth in vitro and also in immune-
deficient mice. We found that ROR1 could interact with casein kinase 1 epsilon (CK1e) to activate phosphoinositide 3-kinase-
mediated AKT phosphorylation and cAMP-response-element-binding protein (CREB), which was associated with enhanced
tumor-cell growth. Wnt5a, a ligand of ROR1, could induce ROR1-dependent signaling and enhance cell growth. This study
demonstrates that ROR1 is expressed in human breast cancers and has biological and clinical significance, indicating that it
may be a potential target for breast cancer therapy.
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Introduction
The receptor-tyrosine-kinase-like orphan receptor 1 (ROR1)
was identified by a polymerase chain reaction (PCR)-based search
for tyrosine kinases similar to the tropomyocin receptor kinase
(Trk) neurotropic receptors [1]. ROR1 and a related protein,
ROR2, were identified as orphan receptors with an extracellular
Frizzled-like, cysteine-rich domain, an extracellular, membrane-
proximal kringle domain, and an intracellular tyrosine-kinase-like
domain [2]. Both ROR proteins are evolutionarily conserved
among different species [1,2,3,4,5]. These proteins are primarily
expressed during embryogenesis, being most prominent in the
developing face, limbs, heart, and lungs. ROR2 knockout mice
exhibited dwarfism and cardiac dysfunction leading to neonatal
lethality [6,7]. ROR1-deficient mice, on the other hand, did not
exhibit any morphological abnormalities during embryogenesis,
but died within 24 hours after birth, presumably due to respiratory
failure caused by inadequate development of the muscles required
for ventilation [8]. Although mutations in human ROR2 have
been implicated in causing certain congenital skeletal defects,
including shortened or missing digits and a form of short-limbed
dwarfism [9,10,11], mutations in ROR1 have not been reported in
any human disease.
In prior studies, we and others found that ROR1 was expressed
by leukemia cells and some cancer cell lines, and was involved in
cell survival [10,12,13,14,15,16,17,18]. However, it was not
known whether other cancers expressed ROR1 or whether its
expression had functional and clinical significance. Here, we used
a high-affinity mAb specific for ROR1 (named 4A5 [10]) to
examine human breast cancers. Our results reveal that human
breast cancers express ROR1, which can contribute to tumor-cell
growth and survival via activation of PI3K, AKT, and CREB.
Results
The Neoplastic Cells of Human Breast Cancers Express
ROR1
Evaluation of fresh-frozen tumor biopsy specimens (N=4) with
4A5 revealed that breast adenocarcinomas expressed ROR1, in
contrast to normal breast tissues (N= 2) which lacks expression of
ROR1 [13]. 4A5 also did not bind to stromal cells present in
breast tissue (Fig. 1A). A ROR1 protein with a molecular size of
<120 kD could be detected in tumor-tissue lysates (Fig. 1B). This
size was comparable to that of ROR1 identified in Chinese
Hamster Ovary (CHO) cells transduced to express human ROR1
(CHO-ROR1) [10]. Many breast cancer cell lines also expressed
surface ROR1 (Fig. 1C). On the other hand, some breast cancer
cell lines lacked detectable ROR1 (e.g. MCF-7).
4A5 also specifically reacted with ROR1-positive cells that had
been fixed in formalin (Fig. 1D). This allowed us to examine tissue
microarrays for expression of ROR1 by neoplastic breast cancer
specimens of different patients (N= 113) or by normal adult breast
tissues (N= 15). The neoplastic cells of high proportions of human
breast cancers expressed ROR1, which was not detected on
normal breast tissues or the non-neoplastic stromal cells in breast
cancer tissue specimens (Fig. 1E–F). The expression levels of
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Figure 1. ROR1 is expressed in human breast cancers and breast cancer cell lines. (A) Representative images of fresh frozen tissue sections
stained for immunohistochemistry with 4A5, a mAb specific for ROR1 (labeled anti-ROR1) or an IgG2b isotype-control mAb (labeled IgG). The bound
antibody is red and the nuclear counterstain with hematoxylin is blue. Red arrow points to the tumor cells and blue arrow points to stromal cells. (B)
Immunoblot analysis of lysates from normal human breast tissue or breast cancer tissue with rabbit antibodies specific for human ROR1 or b-Actin.
CHO-ROR1 cells are CHO cells transfected to express human ROR1. (C) Fluorescence histograms of human breast cancer cell-lines (MCF-7, SKBR3,
MDA-MB-431, MDA-MB-468, or MDA-MB-231) stained with 4A5 (open histograms) or control mAb (shaded histograms) (top panel). The expression of
ROR1 mRNA in each tumor cell line relative to MCF-7 cells assessed via quantitative RT-PCR is indicated by the relative height of each bar below the
corresponding histogram. The error bars represent the standard error about the mean of triplicate values. (D) Formalin-fixed, paraffin-embedded
pellets of MCF-7 or MDA-MB-231 cells were stained with 4A5 or control IgG2b. Tissue-bound 4A5 is shown in red and the nuclear counterstain with
hematoxylin is in blue (Scale bar in the top left picture represents 35 mm). (E) Representative images of breast normal tissues or cancer tissues stained
with 4A5 A score of 0 indicates that none of the cells within the sample bound to the anti-ROR1 mAb; a score of 1 indicates low-level binding of the
mAb to the tumor cells or low-to-moderate-level binding of the mAb on less than 50% of tumor cells; a score of 2 indicates moderate-level staining
on more than 50% of tumor cells or high-level staining of the tumor cells. The scale bar in the top right picture represents 35 mM. Red arrows point to
the tumor cells, blue arrow points to stromal cells and green arrow points to lymphocytes. (F) The proportion of breast tumor tissues or normal
tissues found negative (Score 0) or having weak to moderate staining (Score 1) or strong staining (Score 2) for ROR1 are indicated by in each bar. The
number of different cases examined for each tumor type is indicated in the parentheses. (G) The proportion of different histological types of breast
tumor tissues found lacking staining (Score 0) or having weak to moderate staining (Score 1) or strong staining (Score 2) for ROR1 are indicated by in
each bar. The number of different cases examined for each tumor type is indicated in the parentheses. (H) The proportion of poorly differentiated
(grade 3) or well to moderately differentiated (grade 1–2) ductal breast adenocarcinoma tissues found lacking staining (Score 0) or having weak to
moderate staining (Score 1) or strong staining (Score 2) for ROR1 are indicated by in each bar. The number of different cases examined for each tumor
type is indicated in the parentheses. Statistical significance of the differences was analyzed using Kruskal-Wallis test (Grade 3 versus grade 1–2,
P = 0.013).
doi:10.1371/journal.pone.0031127.g001
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ROR1 varied between specimens from different patients. The 4A5
mAb stained the breast cancer cells intensely in forty percent of
specimens from different patients (N=112) and weak to
moderately in 33% of the specimens via immunohistochemistry
(Fig. 1E–F). We also found that 7 of 12 (55%) patients with lobular
breast adenocarcinoma had breast cancer tissue that had high-
level expression of ROR1, whereas only 21 of 71 (29%) patients
with ductal breast adenocarcinoma had cancer tissue that stained
intensely with 4A5 (Fig. 1G). Moreover, 10 out of 14 (72%)
patients with poorly differentiated ductal breast adenocarcinoma
(grade 3) had cancer tissue that expressed high levels of ROR1
protein. this proportion (72%) was significantly higher than the
19% of patients (N=57) with moderately-differentiated ductal
adenocarcinoma (grade 1–2) that expressed high levels of ROR1
(p = 0.013, Kruskal-Wallis test, Fig. 1H)
Expression Of ROR1 In Human Breast Cancer Is
Associated With Adverse Disease Characteristics
We found ROR1 was expressed on the estrogen-receptor-
negative breast cancer cell lines MDA-MB-231 or MDA-MB-468,
but not on the estrogen-receptor-positive breast cancer cell lines
MCF-7 or SKBR3 [19] (Fig. 1C). Because of this, we interrogated
published DNA microarray datasets on primary human breast
cancers and cancer cell lines for expression of ROR1 and
hormone receptors [19,20,21]. We noted that many of the breast
cancer cell lines included in a dataset published by Neve and
colleagues [19] had levels of ROR1 comparable to that of MDA-
MB-231 or MDA-MB-468. These ROR1-positive cell lines
generally also lacked expression of estrogen receptors, or
estrogen/progesterone receptors and HER2/Neu (triple-negative)
(Fig. 2A and Fig. S1A). We also found that primary breast cancer
tissues that either were poorly differentiated (grade 3), lacked
expression of estrogen receptors, or were triple negative, generally
expressed higher levels of ROR1 than primary breast cancer tissues
without such poor-prognostic features (Fig. 2B, S1B–C). Finally,
Kaplan-Meier survival analysis revealed an association between
higher expression levels or ROR1 and shorter overall survival
times (p,0.05) (Fig. 2C). These data suggest that breast-cancer
expression of ROR1 is a characteristic associated with poorly
differentiated breast cancers that generally have an adverse clinical
outcome.
ROR1 Promotes Tumor-Cell Survival And Growth
We transduced MDA-MB-231 with vectors encoding short-
hairpin RNAs that could either specifically silence ROR1 (ROR1-
shRNA) or serve as a control (Ct-shRNA). We found that MDA-
MB-231 cells had higher proportions of cells undergoing apoptosis
following silencing of ROR1 than MDA-MB-231 cells transduced
with Ct-shRNA (Fig. 3A–B). We selected cells of MDA-MB-231
silenced for ROR1 that maintained negligible expression of
ROR1 (Fig. S2A). MDA-MB-231 cells silenced for ROR1 had a
significantly smaller BrdU-labeling index than did cells cultured
from MDA-MB-231 cells that were transduced with Ct-shRNA
and maintained expression of ROR1 (Fig. S2B). MDA-MB-231
silenced for ROR1 also had reduced growth rates relative to that
of MDA-MB-231 cells treated with Ct-shRNA (Fig. 3C).
Control-treated and ROR1-silenced MDA-MB-231 cells were
transfected with a lentivirus encoding GFP and luciferase and
selected for expression of GFP [22]. When equal numbers of such
cells were implanted into female immune deficient RAG2/2/cc
2/2
mice we observed significant differences in their mean fluorescence
intensities at three weeks. Moreover, the mean fluorescence
intensity of the tumors derived from control-treated cells was 4
times greater than that of tumors silenced for ROR1 when imaged
thirty days after implantation (Fig. 3D). Tumors from cells silenced
for ROR1 had lower ROR1 expression, 5 times more apoptotic
cells, and significantly lower proportions of cells that stained for the
proliferation marker Ki-67 than did tumors derived from control-
treated tumor cells (Fig. 3E).
Expression Of ROR1 Enhances Activation Of CREB
We examined the gene expression profiles of MDA-MB-231
cells silenced for ROR1 or transduced with Ct-shRNA. We
adopted a network-based classification scheme that combines gene
expression measurements over groups of genes that fall within
common pathways [23]. Cells silenced for ROR1 had lower
expression levels of genes encoding proteins induced by CREB
than control-treated cells (Fig. S3A). The transcriptional expres-
sion levels of 38% of all CREB bound genes were decreased in
cells silenced for ROR1 relative to that of control cells. Cells
silenced for ROR1 had reduced expression of 45% or 40% of the
CREB-bound genes encoding proteins involved in cell prolifera-
tion or apoptosis, respectively (Fig. S3B–C and Table S1).
Figure 2. Expression of ROR1 in human breast cancer is associated with aggressive disease. (A) Each bar represents median-centered
log2 expression of ROR1 mRNA by breast cancer cell lines in Vene dataset. Cell lines with similar molecular characteristics are clustered together. (B)
Each dot plot represents median-centered log2 expression of ROR1 mRNA by tumor tissue from an individual patient. Patient samples with similar
phenotypic or molecular characteristics are clustered together. The line indicates the median ROR1 expression level by the group. P indicates the
statistical significance of the differences in the collective ROR1 expression between the two groups, as calculated using Student’s t test. (C) Kaplan-
Meier survival analysis for 295 breast cancer patients from Vandevijver dataset using defined cut-off values for ROR1 expression (patient sub-groups
defined as samples that expressed ROR1 at levels that exceeded that of the mean level of ROR1 expressed by all samples (50% high: n = 148), highest
20% (20% high: n = 58) or highest 10% (10% high: n = 30) relative ROR1 expression. Statistical difference was determined by log-rank test. The each
dataset used is indicated on the top of each graph.
doi:10.1371/journal.pone.0031127.g002
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Moreover, MDA-MB-231 cells silenced for ROR1 had relatively
low expression of 70% of the CREB-bound genes in 29 of 49 genes
contained with the 70 gene prognostic-signature associated with
tumor specimens from patients with aggressive disease [24] (Fig.
S3D and Table S2). Quantitative RT-PCR analysis validated
these findings for selected genes. In particular, we found that cells
silenced for ROR1 had lower expression levels of CCNB1, BCL2,
and CCND1 than did control-treated cells (Fig. 4A). The proteins
encoded by these genes also were expressed at lower levels in
MDA-MB-231 cells silenced for ROR1 than in control-treated
cells (Fig. 4B).
We examined cells for phosphorylated CREB (p-CREB) at
serine-133 (Ser-133), which is a feature of activated CREB [25].
MDA-MB-231 cells silenced for ROR1 had significantly lower
levels of p-CREB relative to that of MDA-MB-231 cells that were
transfected with Ct-shRNA (Fig. 4C). Lower levels of p-CREB also
were found in tumors that developed from cells silenced for ROR1
than in tumors that developed from control-treated cells (Fig. 4D,
upper panel). Furthermore, expression of CREB-target genes was
reduced in tumors derived from MDA-MB-231 cancer cells than
that in tumors silenced for ROR1 (Fig. 4D, lower panel).
We also transduced MDA-MB-231 cells with an adenovirus
vector encoding either a dominant-negative CREB (Ad-ACREB)
or green fluorescence protein (Ad-GFP). Cells transduced with Ad-
ACREB had reduced expression of CREB-target genes than cells
transduced with Ad-GFP (Fig. 4E). Moreover, after three days,
cultures of tumor cells transduced with Ad-ACREB had
significantly lower proportions of viable cells than cultures of cells
transduced with Ad-GFP. On the other hand, there were no
apparent differences in growth of cells silenced for ROR1
following transduction with Ad-ACREB or Ad-GFP (Fig. 4F).
Similar effects were obtained when CREB was silenced using
Figure 3. Expression of ROR1 promotes tumor-cell survival and growth. (A–B) MDA-MB-231 cells transiently transduced with control shRNA
(Ct-shRNA1 or 2) or ROR1-shRNA1 or 2, as indicated at the top of each lane, were examined for ROR1 expression by immunoblot analysis (A) or
stained with Annexin V for apoptosis detection after 2 days (B). The height of each bar in the graph B indicates the mean proportion of cells that were
Annexin-V positive. The error bars indicate the standard error of triplicate samples. P indicates the statistical significance as measured by Dunnett’s
multiple comparisons test. * indicates P,0.05. (C) MDA-MB-231 cells were transduced with vectors encoding Ct-shRNA or ROR1-shRNA and then
selected for stable expression of the shRNA. Equal numbers of cells indicated in the legend provided in the top left corner were cultured and
monitored for growth over time. Each graph indicates the average number of viable cells assessed at 0, 1, 2, or 3 days using the WST-8 assay. The
error bars indicate the S.E. of the mean for triplicate samples. * indicates P,0.05 and ** indicates P,0.01(Student’s t test). (D) Representative
bioluminescent imaging of RAG2/2/cc
2/2 mice engrafted with luciferase-labeled MDA-MB-231 cells transduced with Ct-shRNA1 (top row) or ROR1-
shRNA1 (bottom row). The intensity of the fluorescence signal related to cell number is indicated by the scale on the bottom. The graph on the right
provides the mean fluorescence activity of RAG2/2/cc
2/2 mice engrafted with luciferase-labeled MDA-MB-231 cells transduced with Ct-shRNA1
(closed triangles) or ROR1-shRNA1 (open triangles) at various times after engraftment, as indicated by the legend in the upper left corner. The error
bars indicate S.E.M. fluorescence activity of groups of mice (n = 5–7) at each time point. ** indicates P,0.01(Student’s t test). (E) Tumors were
extracted from mice engrafted with MDA-MB-231 cells transduced with Ct-shRNA1 or ROR1-shRNA1 and examined for ROR1 (left), TUNNEL (middle),
or Ki-67 (right). The scale bar in the top right panel corresponds to 35 mm. The nuclear counterstain is in blue and antibody staining is in red. The
height of each bar on the right graph indicates the proportion of Tunel-positive or Ki67-positive cells in tumors that formed from MDA-MB-231 cells
transduced with either Ct-shRNA or ROR1-shRNA. Error bars indicate S.E.M (n = 7). * indicates P,0.05 (Student’s t test).
doi:10.1371/journal.pone.0031127.g003
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CREB siRNA (Fig. S4A). Finally, we examined paraffin-
embedded primary human breast tumor tissues for ROR1 and
p-CREB, and scored them on the basis of their intensity of staining
for ROR1 or p-CREB. We observed a significant association
between expression of ROR1 and p-CREB in primary tumors
(N= 36, P,0.05, x2 test, Fig. 4G and Table S3). Collectively,
these results indicate that activation of CREB is associated with
expression of ROR1 in MDA-MB-231.
We examined for activation of signaling proteins upstream of p-
CREB, such as AKT or phosphoinositol 39 kinase (PI3K) [26]. We
found MDA-MB-231 cells silenced for ROR1 had lower levels of p-
AKT relative to AKT than control-treated cells (Fig. 5A). On the
other hand, treatment with a PI3K inhibitor (LY294002) reduced
the levels of p-AKT and p-CREB in MDA-MB-231 cells that
expressed ROR1 (Fig. 5B). Moreover, ROR1-expressing MDA-
MB-231 cells were more sensitive to the growth-inhibitory activity
of LY294002 thanMDA-MB-231 cells silenced for ROR1 (Fig. 5C).
A similar relationship between p-CREB and ROR1 was
observed in MCF-7 cells transduced to express ROR1. MCF-7
made to express ROR1 had increased levels of p-AKT and p-
CREB, greater expression of CREB-target genes, and more rapid
cell growth in vitro than ROR1-negative MCF-7 cells transduced
with a control vector (Fig. 5D–E).
We immune-precipitated ROR1 in lysates of MDA-MB-231 cells
and evaluated whether the ROR1-immune precipitate contained
casein kinase 1 epsilon (CK1e), a kinase found capable of associating
with ROR2 [27] that may activate AKT [28]. We found ROR1 was
associated with CK1e (Fig. 5F). Inhibiting expression or function of
CK1e by respective treatment of MDA-MB-231 cells with CK1e
siRNA or a CK1e inhibitor, IC261, reduced the levels of p-AKT
and p-CREB relative to AKT and CREB (Fig. 5G, Fig. S4B). Such
treatment also significantly reduced the growth of MDA-MB-231
cells, but had less effect on MDA-MB-231 cells previously silenced
for ROR1 (Figure 5H, Fig. S4C).
Role Of Wnt5a In ROR1-Dependent Activation Of PI3K/
AKT/CREB Signaling And Enhanced Tumor Growth
Prior studies demonstrated that ROR1 could serve as a receptor
for Wnt5a [10]. To evaluate the response of ROR1 to this ligand
Figure 4. ROR1 activates CREB to regulate tumor-cell growth. (A) Relative expression of selected genes by MDA-MB-231 cells transduced with
either Ct-shRNA (white bars) or ROR1-shRNA (black bars), as assessed via quantitative RT-PCR. The numbers on the y-axis represent fold difference in
specific gene expression relative to GAPDH. Error bars indicate S.E.M. (n = 3 experiments). * indicates P,0.05, ** indicates P,0.01 and *** indicates
P,0.001 (Student’s t test). (B) Immunoblot analyses for proteins listed on the right margin, using lysates from MDA-MB-231 control cells versus cells
silenced for ROR1. (C) Immunoblot analysis of CREB phosphorylation at ser-133 (p-CREB), total CREB (t-CREB), ROR1, or b-Actin for MDA-MB-231 cells
with or without ROR1 silencing, as indicated on the top of each panel. The phospho-specific antibody recognizes phospho-serine-133 CREB. (D)
Tumors extracted from mice engrafted with MDA-MB-231 control cells or ROR1-shRNA-transduced cells were examined for p-CREB by
immunohistochemistry staining (n = 3) or Bcl-2, Cyclin D1 and b-Actin protein expression by immunoblot analysis. The scale bar in the left panels
represents 35 mm. The antibody staining is in red and the nuclear counterstain is in blue. The intensity of p-CREB was quantified and data were
represented as mean intensity 6 S.E.M from 3 tumor tissues per group. (E) MDA-MB-231 cells infected with Ad-GFP or Ad-ACREB were examined for
expression of proteins by immunoblot analyses. (F) MDA-MB-231tumor cells with or without ROR1 expression were transfected with Ad-GFP or Ad-
ACREB and then monitored for cell growth. The numbers of viable cells (after 72 hours culture) are represented by the height of each bar in the
graph. The error bars provide the S.E.M. of triplicate samples. P indicates the statistical significance as assessed by Student’s t test. (G) Representative
images of breast cancer tissues stained for phospho-CREB (p-CREB) (top panels) or ROR1 (bottom panels). Tissue-bound antibody is shown in red and
the nuclear counterstain with hematoxylin is in blue. The scale bar in the top left picture represents 35 mM. Tissues were scored as 0 (none of the cells
within the sample bound to the mAb); 1 (low-level binding of the mAb to the tumor cells or low-to-moderate-level binding of the mAb on less than
50% of tumor cells); 2 (moderate-level staining on more than 50% of tumor cells or high-level staining of the tumor cells). Red arrows point to the
tumor cells, blue arrow points to stromal cells and green arrow points to lymphocytes.
doi:10.1371/journal.pone.0031127.g004
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in breast cancer cells, MDA-MB-231 cells that express low-levels
of Wnt5a (Fig. S5A) were transfected with increasing amounts of
vector encoding human Wnt5a together with a vector encoding a
Cre-luciferase reporter construct. The relative luciferase activity
was increased by transfection of MDA-MB-231 cells with the
Wnt5a construct in a dose dependent fashion (Fig. 6A). This effect
was not observed using MDA-MB-231 cells previously silenced for
ROR1 (Fig. 6A). Treatment of MDA-MB-231 cells with
recombinant Wnt5a (rWnt5a) also enhanced the levels of p-
AKT and p-CREB, and induced higher expression of CREB-
target genes in MDA-MB-231 cells, but not in cells silenced for
ROR1 (Fig. 6B–C). Furthermore, treatment of cells with rWnt5a
increased the number of viable MDA-MB-231 cells in a dose-
dependent manner (Fig. S5B), but not MDA-MB-231 cells lacking
ROR1 (Fig. 6D). Treatment of MDA-MB-231 cells with
LY294002 could block Wnt5a-induced phosphorylation of AKT
and CREB (Fig. 6E). The capacity of Wnt5a to enhance
expression of CREB target genes or to promote tumor-cell growth
also was inhibited by treatment with LY294002 or transduction of
the cells with Ad-ACREB (Fig. 6F–G).
Discussion
Here we present data demonstrating that high proportions of
human breast cancers expressed ROR1. The expression level of
ROR1 varied among patient samples; whereas some cases had
uniform high-level expression of ROR1, others cases had low or
non-detectable levels of this protein. In any case, a sizable fraction
of breast cancers expressed ROR1, which was in contrast to the
non-neoplastic normal breast tissues. Consistent with these
findings, we found that many established breast cancer cell lines
express ROR1. This was corroborated by examination of the gene
expression data on breast cancer cell lines published by Neve et al
[19,29,30,31]]. Moreover, the breast cancer cells that expressed
Figure 5. ROR1 interacts with CK1e to activate PI3K/AKT, leading to activation of CREB. (A) MDA-MB-231tumor cells with or without ROR1
expression were examined for phosphorylated AKT at ser-473 (p-AKT) or total AKT (t-AKT). (B) MDA-MB-231 cells were cultured with (+) or without (2)
LY294002 and examined for p-AKT, t-AKT, p-CREB, or t-CREB by immunobot analysis after 16 hours. (C) MDA-MB-231 cells (Ct-shRNA) or cells silenced
for ROR1 (ROR1-shRNA) were cultured with different concentrations of LY294002 and monitored for cell growth after 48 hours using the WST-8 assay.
The graphs depict the mean numbers of viable cells, 6 S.E.M of triplicate samples, which are representative of three independent experiments.
*P,0.05 and ***P,0.001). (D–E) MCF7 control cells (Ct-Vector) or cells made to express ROR1 (pCDNA3-ROR1) were examined for protein expression
(D) or (E) monitored for growth over 4 days using the WST-8 assay. The graph depicts the mean numbers of viable cells 6 S.E.M. over time in each of
these cell lines, as indicated in the legend at the top of the figure, which are representative of three independent experiments. *P,0.05, **P,0.01
and ***P,0.001 by Student’s t test. (F) Protein lysates from MDA-MB-231 cells or cells silenced for ROR1 were immunoprecipitated (IP) with ROR1
antibody. The bound immunoprecipitated products and whole cell lysate (WCL) were probed by the antibodies indicated in the Probe column. (G–H)
MDA-MB-231 cells were treated without (2) or with CK1e siRNA (CK1e-siRNA) or control siRNA (Ct-siRNA) for 72 hours and examined for protein
expression (G) or cell growth (H). The height of each bar in the graph F provides the mean number of viable cells6 S.E.M., which are representative of
more than three independent experiments. P indicates the statistical significance.
doi:10.1371/journal.pone.0031127.g005
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ROR1 generally lacked expression of hormone receptors and/or
HER2/neu, which was in contrast to most breast cancer cells lines
found to lack expression of ROR1.
Two individual gene expression data were used to evaluate
whether breast cancers that expressed ROR1 had clinical
significance distinct from that of ROR1-negative tumors. The
patients from Vandevijver dataset had stage I or II breast cancer
and were younger than 53 years of age. The predictive power of
the prognosis profile was evaluated using either univariable or
multivariable statistical analyses. On the other hand, the patients
from the Hess breast cancer study had stage I–III breast cancer
[20,21]. In either dataset, we found that primary breast cancers
that expressed high-levels of ROR1 were more likely to lack
expression of estrogen or progesterone receptors or HER2/Neu,
consistent with the observation in breast cancer cell lines.
Conceivably, tumors that are poorly differentiated are more likely
to express ROR1, a protein that normally is expressed by
embryonic cells. Patients who had primary breast cancers that
expressed higher levels of ROR1 had a significantly shorter
median survival than did patients with primary breast cancers that
had low-to-negligible expression of ROR1. As such, expression of
ROR1 appears associated with aggressive disease in human breast
cancer.
We silenced ROR1 expression in breast cancer cell lines to
evaluate its function on tumors. When silenced for ROR1, cancer
cells were more sensitive to spontaneous apoptosis and had an
impaired cell growth. On the other hand, MCF-7 cells that were
transduced to express ROR1 had more aggressive growth
characteristics than did control MCF-7 cells. Collectively, our
studies indicate that expression of ROR1 is conducive to cancer-
cell growth.
One study found that the activity of ROR1 in NCI-1993 cells
was dependent upon the expression of MET, a proto-oncogene
that encodes the hepatocyte growth factor receptor (HGFR) [18].
Figure 6. Wnt5a is involved in ROR1-mediated signaling and cell growth. (A) MDA-MB-231 cells (Ct-shRNA) or cells transduced for ROR1-
shRNA (ROR1-shRNA) were transfected with Cre-luciferase reporter construct and/or increasing amounts of Wnt5a expression vector. The bars
provide the mean relative luciferase activity of the various cell populations. *P,0.05 by Dunnett’s multiple comparisons test. (B–D) MDA-MB-231 cells
or cells silenced for ROR1 were stimulated with/without 250 ng/ml exogenous recombinant Wnt5a protein (rWnt5a) and examined for p-AKT, AKT, p-
CREB, CREB at 15 minutes (B), BCL-2, ROR1 and b-actin expression at 48 hours (C) and cell growth at 48 hours (D). The graph depicts the mean
numbers of viable cells 6 S.E.M., which is representative of more than three independent experiments. (E) MDA-MB-231 cells were pretreated with/
without 10 mM LY294002 for 2 hours and then stimulated with/without 250 ng/ml rWnt5a for 15 minutes and examined for protein expression.
Relative phospho-protein levels were normalized to total-protein. (F–G) MDA-MB-231 cells were treated with/without 10 mM LY294002, or infected
with either Ad-GFP or Ad-ACREB, or cultured in the media with/without 250 ng/ml rWnt5a for 48 hours as indicated on the top, and examined for
proteins (F) or cell growth using WST-8 assay (G). The height of each bar in the graph provides the mean number of viable cells 6 S.E.M. in each cell
population. P indicates the statistical significance as determined using Student’s t test. (H) Model of ROR1 promoting tumor-cell growth. Wnt5a
expressed by tumor or tumor microenviroment (e.g. stromal cell) interacts with ROR1 to activate PI3K/AKT through CK1e, leading to activation of
CREB to enhance expression of genes that enhance resistance to tumor cell apoptosis and/or promote tumor cell growth.
doi:10.1371/journal.pone.0031127.g006
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However, the MDA-MB-231 or MCF-7 cells used in the current
study respectively expressed low or negligible levels of MET (Fig.
S6), making it less unlikely that expression of MET is required for
ROR1 function. Moreover, the neoplastic cells in chronic
lymphocytic leukemia also appear dependent upon expression of
ROR1 [17], but do not express MET (Fig. S6), suggesting that the
function ROR1 also does not require HGFR in primary tumor
cells.
Instead, the current study highlights an important role played
by CREB, a transcription factor that is over-expressed and
constitutively phosphorylated in a number of human cancers and
that appears to play a direct role in tumor pathogenesis and
prognosis [32,33,34,35,36,37,38]. MDA-MB-231 cells silenced for
ROR1 expressed lower levels of CREB-target genes, many of
which are expressed by breast cancers of patients with aggressive
disease [21,24]. Furthermore, transduction of cancer cells with the
dominant negative CREB (ACREB) inhibited expression of
CREB-target genes and reduced the growth of cancer cell lines
that expressed ROR1, implying that activation of CREB
contributes to the enhanced tumor-growth characteristics afforded
by expression of ROR1.
Prior studies found that activation of AKT could directly induce
phosphorylation of CREB at Ser-133 [26]. We found that AKT
was activated in cancer cells that expressed ROR1, but not in cells
that were silenced for ROR1. We also found ROR1 could
associate with CK1e, which was reported to promote the
activation of AKT and the survival and proliferation of cancer
cells [28,39]. Treatment of MDA-MB-231 cells with inhibitors of
PI3K or CK1e, or silencing expression of CK1e, also could impair
activation of CREB and reduce the numbers of viable cells relative
to that of control-treated cells. Blocking PI3K/AKT signaling also
blocked the capacity of Wnt5a to enhance phosphorylation of
AKT or CREB, expression of CREB target genes, or cell growth.
Previously we found that Wnt5a could bind ROR1 and
enhance the survival of CLL cells, which expressed ROR1, but
lacked expression of Wnt5a [40]. Because marrow stromal cells
capable of supporting CLL cell survival express Wnt5a, we
hypothesized that Wnt5a could function in a paracrine manner to
support CLL-cell survival. Indeed, in this study, we found that
exogenous Wnt5a could enhance the phosphorylation of AKT and
CREB, the expression of CREB-target genes, and the growth of
tumor cells that expressed low-levels of Wnt5a, indicating that
Wnt5a could act in a paracrine manner for such tumors [41].
However, because some cancer cells have been noted to express
Wnt5a [42,43], it is conceivable Wnt5a also might serve as an
autocrine that can enhance the growth of turmors that co-express
ROR1.
Based upon these collective results we propose that ROR1
interacts with CK1e to activate PI3K/AKT/CREB, which in turn
induces expression of genes that can enhance resistance to
apoptosis and/or promote tumor cell growth (Fig. 6E). The results
presented here indicate that a substantial subset of human breast
cancers expresses ROR1 and such expression may be associated
with aggressive disease. Because of the selective expression of
ROR1 by neoplastic cells and its apparent role in promoting
tumor-cell growth, ROR1 may serve as a potential target for
development of anti-cancer therapies.
Methods
Ethics statement
The project was reviewed and approved by one of UCSD’s
Institutional Review Board (IRB) in accordance with the
requirements of the Code of Federal Regulations on the Protection
of Human subjects (45 CFR 46 and 21 CFR 50 and 56), including
its relevant subparts. IRB#080918
All experiments on mice were conducted in accordance with the
guidelines of National Institutes of Health (NIH; Bethesda, MD,
USA) for the care and use of laboratory animals. The study
protocol was approved by UCSD and Medical Experimental
Animal Care Committee (USA). Approval#: S02145
Cell culture
Cancer cell-lines were purchased from the American Type
Culture Collection (ATCC, Manassas, VA, USA). All cell-lines
were cultured at 37uC in a 5% CO2/95% humidified air
incubator in Dulbecco’s modified Eagle medium (DMEM,
Invitrogen, Carlsbad, CA) with 10% fetal bovine serum (FBS,
Invitrogen), 50 mg of penicillin G, and 50 mg of streptomycin
sulfate. We added puromycin (1 mg/ml) to MDA-MB-231 cells or
G418 (1.5 mg/ml) to MCF-7 cells transduced with lentivirus
encoding Ct-shRNA or ROR1-shRNA, or transfected with
pCDNA3-ROR1 or pCDNA3. Stable transfectants were selected
by flow cytometry.
Immunohistochemistry
Tissue microarray (TMA) slides and frozen tissues were
purchased from the National Development and Research
Institutes, Inc. (NDRI, New York, NY) or Cooperative Human
Tissue Network (CHTN, Virginia) Tissue Microarray.. After IRB
approval, immunohistochemical staining (IHC), using DAKO
Universal LSAB2 kit (DAKO, Denmark), was performed to detect
ROR1, Ki67, or phosphor-CREB. Tunel staining was performed
with the ABC Vecrastain kit (Vector) and the AEC-cobalt-nickel
staining kit according to the manufacturer’s directions. The level
of ROR1 or p-CREB was scored on the following scale: A score of
0 indicates that none of the cells within the sample bound to the
anti-ROR1 mAb; a score of 1 indicates low-level binding of the
mAb to the tumor cells or low-to-moderate-level binding of the
mAb on less than 50% of tumor cells; a score of 2 indicates
moderate-level staining on more than 50% of tumor cells or high-
level staining of the tumor cells. Scoring of the tissue microarray
was performed in a blinded-fashion by a board-certified
pathologist. The signal intensity of phosphor-CREB for tumors
xenografted in mice was determined by Image-Pro Plus image
analysis software following a previous method [44]. The integrated
optical density (IOD) represented averages from 10 non-
overlapping images of each tumor specimen. All quantitative
studies were performed blinded with regards to animal genotype.
Cell proliferation assay
Cell proliferation was analyzed using ‘‘Cell-Counting Kit
Solution’’ (CCK-8) (Dojindo, Kumamoto, Japan). Cells were
plated in 96-well plates at 1–56103 cells/well and maintained at
37uC in a humidified incubator with vehicle or recombinant
Wnt5a protein (R & D Systems, Minneapolis, MN). 10 ml of CCK-
8 was added to each well at different time points and cells were
incubated for 3 hours. The absorbance at 450 nm was measured
to calculate the numbers of viable cells in each well.
Silencing of human ROR1, CK1e, or CREB
Virapower lentivirus expression system (Invitrogen) was used for
the expression of shRNA according to the manufacturer’s
instructions. The constructs of ROR1-shRNA1 and Ct-shRNA1
encode red fluorescence protein (RFP). Oligonucleotides for
ROR1-shRNA1 and non-targeting (Ct-shRNA1) construct were
synthesized (Integrated DNA Technologies) and inserted into the
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RFP-pLKO.1 vector. ROR1-shRNA2 and non-targeting (Ct-
shRNA2) constructs were purchased from Open Biosystems
(Rockford, IL). CK1e siRNA or non-targeting (control) were
synthesized by Invitrogen, CREB1 siRNA were purchased from
Ambion. All siRNA transfections were performed in DMEM
serum-free medium using lipofectaimine RNAiMAX (Invitrogen)
according to the manufacturer’s instruction.
Flow cytometry
4A5 or a control mouse IgG2b was conjugated with Alexa Fluor
647 as described [10]. Cells were incubated with antibodies for
20 min at 4uC in staining media (PBS containing 3% FBS and
1 mM 4-(2-hydroxyethyl)-1-piperazine-ethanesulfonic acid
(HEPES), pH=7.4). After that cells were washed twice prior to
analysis on a FACS-Calibur (Becton-Dickinson, San Jose, CA)
using FlowJo software (Tree Star, Inc., Ashland, OR). To evaluate
for apoptosis, cells were stained with 5 mg/ml Annexin V-FITC
(Biovision, Mountain View, CA) in the dark for 15 min at room
temperature.
Immunoblot
Human tissues, CLL cells isolated from patients or cell lines
were lysed in buffer containing 1% NP40, 0.1% SDS, 0.5%
sodium deoxylate, and protease inhibitors in phosphate buffered
saline (PBS, pH=7.2). Size-separated proteins were transferred to
membranes, which then were incubated with primary antibodies
specific for ROR1, Cyclin D1, Bcl-2, Cyclin B1, phosphor-CREB
(ser-133), CREB, phosphor-AKT (Ser-473), AKT (Cell Signaling
Technology, Danvers, MA), Met (R & D Systems, Minneapolis,
MN), Casein kinase 1 epsilon, Wnt5a, or b-Actin (Santa Cruz
Biotechnology, Santa Cruz, CA). After washing the membranes,
they were incubated with secondary antibodies that were
conjugated with horseradish peroxidase. Blots were then prepared
for enhanced chemiluminescence and subsequent autoradiogra-
phy. The protein concentration was determined using a
bicinchoninic acid protein assay (Pierce, Rockford, IL).
Quantitative RT-PCR
Total RNA was prepared from cells using RNeasy Mini kit
(Qiagen, Valencia, CA). One mg of RNA was reverse transcribed
at 42uC for 45 min in a 20 ml of reaction mixture using the
Reverse Transcription System (Promega, Madison, WI). The
reaction mixture for PCR contained 0.2 mm of each primer (see
supplemental experiment procedure), 30 ng of cDNA and 10 ml of
SYBR Green qPCR Kit (Applied Biosystems). Real-time quanti-
tative PCR was performed for 40 cycles of 15 seconds at 95uC and
60 seconds at 60uC, using an ABI 7700 sequence detection system
(Applied Biosystems). The amplified product was determined by
comparing the Ct values of each sample to a standard curve and
normalized by a housekeeping gene, GAPDH. Values are
expressed as fold increase relative to that observed in Ct-shRNA
MDA-MB-231 cells.
Luciferase assay
MDA-MB-231 cells were seeded in 24 well plates. After
24 hours culture, the cells at 70% confluence were transfected
with 0.2 mg Cre-luciferase reporter, 0.05 mg control plasmid
pCMX-b-galactosidase, and 0.1–0.2 mg pCDNA3.1-Wnt5a in
lipofectamine 2000 (Invitrogen). Forty-eight hours after transfec-
tion, cells were harvested for determination of luciferase activity
using a luminometer (MicroBeta TriLux, Gaithersburg, MD). The
luciferase values were normalized for variations in transfection
efficiency by using beta-galactosidase as an internal control,
expressed as relative luciferase activity, and compared with the
designated control cultures. All assays were performed in triplicate.
Immune-deficient mice and growth of human tumor
xenografts
Six to eight week old BALB/c RAG2/2/cc
2/2 mice were
obtained from Dr. Catriona Jamieson (University of California,
San Diego) and housed in laminar-flow cabinets under specific
pathogen-free conditions and fed adlibrium. All experiments on
mice were conducted in accordance with the guidelines of
National Institutes of Health (NIH; Bethesda, MD, USA) for the
care and use of laboratory animals. The study protocol was
approved by UCSD and Medical Experimental Animal Care
Committee (USA). Subconfluent MDA-MB-231 cells transduced
with Ct-shRNA1 or ROR1-shRNA1, with lentivirus containing
GFP and luciferase, were treated with trypsinized, suspended in
serum-free medium (56106 cells/ml), and mixed with an equal
volume of cold Matrigel. Each cell suspension (106 cells in 400 ml)
was injected into the subcutaneous tissue of female RAG2/2/cc
2/2
immune-deficient mice. We detected luciferase signaling in mice
implanted with cells that were transduced to express luciferase
using a sensitive in vivo imaging system (IVIS 200 series, Xenogen,
Alameda, CA), described by Rice and colleagues [45]. Mice were
anesthetized with isoflurane and injected with luciferin (150 mg/kg
intraperitoneal (i.p.) injection) approximately 10 min before
imaging. The total photon flux emission (photons/s) from the
region of interest (ROI) covering the entire tumor was analyzed
with Living ImageTM software (Caliper Life Science, Hopkinton,
MA).
Statistical analyses
The standard x2 test was used to analyze for correlation
between p-CREB expression and ROR1 expression in human
breast tissues. ROR1 expression levels in breast cancer patients
sample with different phenotypic or molecular character were
analyzed by a two-tailed Student’s t test, using either the log ratios
of gene expression values without modification [21] or the
transformed log ratio of the average intensity of ROR1 expression
values [20]. The survival curves of the resulting four groups were
compared using the log rank test. A two-tailed Student’s t test also
was used to examine for statistical differences in levels of apoptosis,
proliferation, or rates of engraftment in RAG2/2/cc
2/2 immu-
nodeficient mice, of paired sample populations of cells transduced
with Ct-shRNA versus ROR1-shRNA. A one-way analysis of
variance (ANOVA) followed by Dunnett’s multiple comparisons
test was used to evaluate the statistical difference in rates of
proliferation or in the luciferase activity for cells. All analyses were
performed using Graphpad Prism software (GraphPad Software,
La Jolla, CA). A P value of less than 0.05 was considered
significant.
BrdU incorporation assay
The level of DNA synthesis was determined by measuring the
amount of 5-bromo-29-deoxyuridine (BrdU) incorporated during a
set labeling period. The cells were starved through culture in
serum-free medium for 36 hours, isolated, and then reseeded in 6-
well plates for culture overnight in culture media. Then 10 mM
BrdU was added to each well and the cells were incubated for
2 hours. After several washes with PBS, the cells were fixed with
4% paraformaldehyde for 30 minutes and then stained with anti-
BrdU-FITC antibody and 7-AAD for cytometry, using procedures
recommended by the manufacturer (BrdU flow kit, Becton
Dickinson, Mountain View, CA).
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Expression Microarray Analysis
Total mRNA from Ct-shRNA MDA-MB-231 stable cell line
and ROR1-shRNA MDA-MB-231 stable cell line were labeled
with Cy5, hybridized to a human Oligo Microarray (Phalanx
Human Whole Genome OneArrayTM, Phalanx Biotech) accord-
ing to the manufacturer’s protocol. Arrays in duplicates were then
scanned using GenePix 4000B scanner (Molecular Devices) and
the probe intensities were extracted and processed using the
GenePix Pro 6.0 software (Molecular Devices). After removing
experimental control probes, the intensities of 30968 probes were
quantile normalized to have similar distributions across all 4
arrays. The normalized intensity of probes derived from the same
gene was collapsed into a single NCBI Entrez gene by the maximal
value in each sample (mapping information is obtained from
Phalanx’s probe annotation table). In total, 15598 genes were
measured at transcription level. Differential expression of genes
was quantified using fold enrichment. Gene functional annotation
regarding cell proliferation, cell apoptosis, CREB signaling,
breast cancer signature was downloaded from MSigDB database
[38]. Gene set enrichment analysis was described by Mootha [23].
All data is MIAME compliant and the raw data has been
deposited in a MIAME complaint database GEO, as detail on the
website http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?token=
dngdzomiqwwwwzc&acc=GSE31631. The accession number is
GSE31631.
Sequence of primers for qPCR
GAPDH primers: 59-GAAGGTGAAGGTCGGAGTC-39 (forward)
59-GAAGATGGTGATGGGATTTC-39 (re-
verse).
CCND1 primers: 59-AATGACCCCGCACGATTTC-39(forward)
59-TCAGGTTCAGGCCTTGCAC-39 (reverse)
BCL2 primers: 59-ACATCGCCCTGTGGATGACT-39 (for-
ward)
59-GGGCCGTACAGTTCCACAAA-39 (re-
verse)
CCNB1 primers: 59-AGCTGCTGCCTGGTGAAGAG-39(forward)
59- GCCATGTTGATCTTCGCCTTA -39(re-
verse)
ROR1 primers: 59-CAACAAGAAGCCTCCCTAATGG-39 (for-
ward)
59-CCTGAGTGACGGCACCTAGAA-39 (re-
verse)
ACTB primers: 59-CGAGAAGATGACCCAGATCATGTT-39
(forward)
59-CCTCGTAGATGGGCACAGTGT-39 (re-
verse)
The shRNA target sequences of human ROR1
59-ATCCGGATTGGAATTCCCATG-39 (ROR1-shRNA1)
59-CTTTACTAGGAGACGCCAATA-39 (ROR1-shRNA2,
Open Biosystem).
The non-target shRNA or siRNA sequence: 59-AGCGGAC-
TAAGTCCATTGC-39
Small interfering RNA (siRNA) for human CREB1 and CK1e
59-GGUGGAAAAUGGACUGGCUtt-39 (CREB-siRNA, Am-
bion siRNA, ID# 109994)
59-CCAGUGUUUGCUUAGUGUCUUCtt-39 (CK1e-siRNA)
Supporting Information
Figure S1 ROR1 expression is up-regulated in patients
with aggressive disease. (A–C) Each dot plot represents
median-centered log2 expression of ROR1 mRNA by cancer cell
lines or tumor tissue from an individual patient. Cancer cell lines
or patient samples with similar molecular and phenotypic
characteristics are clustered together, as indicated at the bottom
of each cluster. Below this designation is indicated the number of
distinct cases in each cluster. The line indicates the median ROR1
expression level by the group. P indicates the statistical significance
of the differences in the collective ROR1 expression between the
two groups, as calculated using Student’s t test. The each dataset
used is indicated on the top of each graph.
(TIF)
Figure S2 Silencing ROR1 protein reduces the rate of
cell growth. (A) MDA-MB-231 tumor cells were transduced with
vectors encoding Ct-shRNA or ROR1-shRNA and then selected
for stable expression of the shRNA. Lysates of each cell type as
indicated on the bottom selected for stable expression of Ct-
shRNA or ROR1-shRNA were examined for ROR1 or b-Actin
via immunoblot analyses. The vector used to transduce the cells is
indicated at the top of each lane. (B) Serum starved MDA-MB-231
cells were labeled with BrdU for 2 hours, and then stained with
anti-BrdU antibody and 7-amino-actinomycin. Contour plots of
MDA-MB-231 cells (Ct-shRNA, left) or cells silenced for ROR1
(ROR1-shRNA, right) depict the different proportions of cells
found within the gated area, which represents cells in S-phase. The
height of each bar in the graph on the right indicates the mean
proportion of cells in S phase that were BrdU positive in MDA-
MB-231 cells transduced with Ct-shRNA or ROR1-shRNA. The
error bars indicate the standard error of triplicate samples. P
indicates the statistical significance as measured by Student’s t test.
(TIF)
Figure S3 Changes of gene expression profiles of MDA-
MB-231 cells following silencing of ROR1. Expression of
1435 CREB-bound genes (A), 193 cell proliferation related genes
of CREB-bound genes (B), 104 cell apoptosis related genes of
CREB-bound genes (C), 10 known breast cancer signature genes
of CREB-bound genes (D) in MDA-MB-231 cells following
silencing of ROR1. Numbers under color bars denote log2 fold
changes of a gene relative to its mean expression across the 4
arrays. Genes were sorted in a descending order of the average
fold-change of control cells over ROR1-shRNA cells. in MDA-
MB-231 cells (Ct-shRNA_rep1 and _rep2) and cells silenced for
ROR1 (ROR1-shRNA_rep3 and _rep4) are shown. Red indicates
genes that are expressed at higher levels by MDA-MB-231 cells
relative to MDA-MB-231 cells silenced for expression of ROR1,
where green indicates genes with higher expression in cells silenced
for ROR1 relative to that of wild-type cells. Black indicates the
genes that are expressed at equal levels in ROR1 positive versus
ROR1-silenced cells. Numbers under color bars denote log2 fold
changes of a gene relative to its mean expression across the 4
arrays. Genes were sorted in a descending order of the average
fold-change of control cells over ROR1-shRNA cells. CREB-
bound genes and gene functions related to cell proliferation and
apoptosis were downloaded from the database of CREB binding
on the promoter [38], MSigDB database (Molecular Signature
Database) and the database of a gene–expression signature in
breast cancer (VandeVijver et al., 2002). We subsequently
validated the expression of genes marked by an asterisk (*) via
quantitative RT-PCR and immunoblot analyses for the encoded
proteins.
(TIF)
Figure S4 Either silencing CREB or inhibiting CK1e
activity is able to abolish ROR1-induced cell growth. (A)
Equal numbers of MDA-MB-231 cells (Ct-shRNA) or ROR1-
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silenced cells (ROR1-shRNA) were seeded, transfected with
control siRNA (Ct-siRNA) or CREB siRNA (CREB-siRNA) and
monitored for growth over 72 hours using the WST-8 assay. The
mean number of viable cells 6 S.E.M. in each condition was
provided in the graph. P indicates the statistical significance as
assessed by Student’s t test. (B) Immunoblot analysis of proteins as
indicated on the right margin for lysates of MDA-MB-231 cells
treated with (+) or without (2) 0.25 mg/ml IC261 for 16 hours. (C)
MDA-MB-231 cells (diamonds) or ROR1-silenced cells (squares)
were treated with increasing doses of IC261, as indicated on the x-
axis, and then incubated with WST-8 to assess cell growth at
48 hours. The graphs provide the mean proportion of viable cells,
6 S.E.M of triplicate samples. The asterisk indicate concentrations
of LY294002 at which significant differences were observed
between the two cell populations ((*P,0.05 and **P,0.01).
(TIF)
Figure S5 Wnt5a protein is expressed in various cancer
cell lines and could enhance the tumor cell growth. (A)
Expression of Wnt5a in various tumor cell-lines. Total cell lysates
of various tumor cell-lines, as indicated at the top of the figure,
were examined via immunoblot analyses using antibodies specific
for Wnt5a or b-Actin, as indicated on the right margin. (B) Equal
numbers of MDA-MB-231 cells were plated in replicate wells of
96-well plates and cultured in media containing vehicle or
increasing concentrations of recombinant Wnt5a protein (rWnt5a)
for 24 hours, as indicated in the legend. The heights of the bars
indicate the mean number of cells harvested from triplicate wells at
0 or 24 hours using the WST-8 assay. *P,0.05 by Dunnett’s
multiple comparisons test.
(TIF)
Figure S6 Immunoblot analyses for Met or ROR1
expression in lysates from various cancer cells as
indicated on the top. b-actin serves as loading control.
(TIF)
Table S1 Gene expression of subnetworks involved in
CREB regulation in ROR1+ versus ROR1-silenced MDA-
MB-231.
(DOCX)
Table S2 Gene expression of 70-signature genes in
ROR1+ versus ROR1-silenced MDA-MB-231.
(DOCX)
Table S3 The correlation of ROR1 expression with p-
CREB in breast cancer patients (x2 test, P,0.05).
(DOCX)
Acknowledgments
We thank Karl Willert for providing recombinant Wnt5a protein, Esther
Avery for assistance in this work and Marc Montminy for providing
adenovirus encoding ACREB.
Author Contributions
Conceived and designed the experiments: SZ LC TJK. Performed the
experiments: SZ LC GC BC GWB JY LT. Analyzed the data: HYC SZ
LC BC GWB TJK. Contributed reagents/materials/analysis tools: JWR.
Wrote the paper: SZ TJK LC. Helped evaluate the pathology of human
samples: JWR.
References
1. Masiakowski P, Carroll RD (1992) A novel family of cell surface receptors with
tyrosine kinase-like domain. J Biol Chem 267: 26181–26190.
2. Katoh M, Katoh M (2005) Identification and characterization of rat Ror1 and
Ror2 genes in silico. Int J Mol Med 15: 533–538.
3. Forrester WC (2002) The Ror receptor tyrosine kinase family. Cell Mol Life Sci
59: 83–96.
4. Oishi I, Takeuchi S, Hashimoto R, Nagabukuro A, Ueda T, et al. (1999) Spatio-
temporally regulated expression of receptor tyrosine kinases, mRor1, mRor2,
during mouse development: implications in development and function of the
nervous system. Genes Cells 4: 41–56.
5. Wilson C, Goberdhan DC, Steller H (1993) Dror, a potential neurotrophic
receptor gene, encodes a Drosophila homolog of the vertebrate Ror family of
Trk-related receptor tyrosine kinases. Proc Natl Acad Sci U S A 90: 7109–7113.
6. DeChiara TM, Kimble RB, Poueymirou WT, Rojas J, Masiakowski P, et al.
(2000) Ror2, encoding a receptor-like tyrosine kinase, is required for cartilage
and growth plate development. Nat Genet 24: 271–274.
7. Takeuchi S, Takeda K, Oishi I, Nomi M, Ikeya M, et al. (2000) Mouse Ror2
receptor tyrosine kinase is required for the heart development and limb
formation. Genes Cells 5: 71–78.
8. Nomi M, Oishi I, Kani S, Suzuki H, Matsuda T, et al. (2001) Loss of mRor1
enhances the heart and skeletal abnormalities in mRor2-deficient mice:
redundant and pleiotropic functions of mRor1 and mRor2 receptor tyrosine
kinases. Mol Cell Biol 21: 8329–8335.
9. Afzal AR, Rajab A, Fenske CD, Oldridge M, Elanko N, et al. (2000) Recessive
Robinow syndrome, allelic to dominant brachydactyly type B, is caused by
mutation of ROR2. Nat Genet 25: 419–422.
10. Fukuda T, Chen L, Endo T, Tang L, Lu D, et al. (2008) Antisera induced by
infusions of autologous Ad-CD154-leukemia B cells identify ROR1 as an
oncofetal antigen and receptor for Wnt5a. Proc Natl Acad Sci U S A 105:
3047–3052.
11. Oldridge M, Fortuna AM, Maringa M, Propping P, Mansour S, et al. (2000)
Dominant mutations in ROR2, encoding an orphan receptor tyrosine kinase,
cause brachydactyly type B. Nat Genet 24: 275–278.
12. Shabani M, Asgarian-Omran H, Jeddi-Tehrani M, Vossough P, Faranoush M,
et al. (2007) Overexpression of orphan receptor tyrosine kinase Ror1 as a
putative tumor-associated antigen in Iranian patients with acute lymphoblastic
leukemia. Tumour Biol 28: 318–326.
13. Baskar S, Kwong KY, Hofer T, Levy JM, Kennedy MG, et al. (2008) Unique
cell surface expression of receptor tyrosine kinase ROR1 in human B-cell
chronic lymphocytic leukemia. Clin Cancer Res 14: 396–404.
14. Daneshmanesh AH, Mikaelsson E, Jeddi-Tehrani M, Bayat AA, Ghods R, et al.
(2008) Ror1, a cell surface receptor tyrosine kinase is expressed in chronic
lymphocytic leukemia and may serve as a putative target for therapy. Int J Cancer
123: 1190–1195.
15. Tyner JW, Deininger MW, Loriaux MM, Chang BH, Gotlib JR, et al. (2009)
RNAi screen for rapid therapeutic target identification in leukemia patients.
Proc Natl Acad Sci U S A 106: 8695–8700.
16. MacKeigan JP, Murphy LO, Blenis J (2005) Sensitized RNAi screen of human
kinases and phosphatases identifies new regulators of apoptosis and chemore-
sistance. Nat Cell Biol 7: 591–600.
17. Choudhury A, Derkow K, Daneshmanesh AH, Mikaelsson E, Kiaii S, et al.
(2010) Silencing of ROR1 and FMOD with siRNA results in apoptosis of CLL
cells. Br J Haematol.
18. Gentile A, Lazzari L, Benvenuti S, Trusolino L, Comoglio PM (2011) Ror1 is a
pseudokinase that is crucial for Met-driven tumorigenesis. Cancer Res 71:
3132–3141.
19. Neve RM, Chin K, Fridlyand J, Yeh J, Baehner FL, et al. (2006) A collection of
breast cancer cell lines for the study of functionally distinct cancer subtypes.
Cancer Cell 10: 515–527.
20. Hess KR, Anderson K, Symmans WF, Valero V, Ibrahim N, et al. (2006)
Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with
paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast
cancer. J Clin Oncol 24: 4236–4244.
21. van de Vijver MJ, He YD, van’t Veer LJ, Dai H, Hart AA, et al. (2002) A gene-
expression signature as a predictor of survival in breast cancer. N Engl J Med
347: 1999–2009.
22. Chicha L, Tussiwand R, Traggiai E, Mazzucchelli L, Bronz L, et al. (2005)
Human adaptive immune system Rag22/2gamma(c)2/2mice. Ann N Y Acad
Sci 1044: 236–243.
23. Mootha VK, Lindgren CM, Eriksson KF, Subramanian A, Sihag S, et al. (2003)
PGC-1alpha-responsive genes involved in oxidative phosphorylation are
coordinately downregulated in human diabetes. Nat Genet 34: 267–273.
24. van ’t Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, et al. (2002) Gene
expression profiling predicts clinical outcome of breast cancer. Nature 415:
530–536.
25. Mayr B, Montminy M (2001) Transcriptional regulation by the phosphoryla-
tion-dependent factor CREB. Nat Rev Mol Cell Biol 2: 599–609.
26. Du K, Montminy M (1998) CREB is a regulatory target for the protein kinase
Akt/PKB. J Biol Chem 273: 32377–32379.
ROR1 Can Contribute to Breast Cancer Cell Growth
PLoS ONE | www.plosone.org 11 March 2012 | Volume 7 | Issue 3 | e31127
27. Kani S, Oishi I, Yamamoto H, Yoda A, Suzuki H, et al. (2004) The receptor
tyrosine kinase Ror2 associates with and is activated by casein kinase Iepsilon.
J Biol Chem 279: 50102–50109.
28. Modak C, Bryant P (2008) Casein Kinase I epsilon positively regulates the Akt
pathway in breast cancer cell lines. Biochem Biophys Res Commun 368: 801–807.
29. Rakha EA, El-Sayed ME, Green AR, Lee AH, Robertson JF, et al. (2007)
Prognostic markers in triple-negative breast cancer. Cancer 109: 25–32.
30. McGuire WL (1975) Current status of estrogen receptors in human breast
cancer. Cancer 36: 638–644.
31. Stoll BA (1979) Endocrine therapy in cancer. Practitioner 222: 211–217.
32. Aggarwal S, Kim SW, Ryu SH, Chung WC, Koo JS (2008) Growth suppression
of lung cancer cells by targeting cyclic AMP response element-binding protein.
Cancer Res 68: 981–988.
33. Cheng JC, Kinjo K, Judelson DR, Chang J, Wu WS, et al. (2008) CREB is a
critical regulator of normal hematopoiesis and leukemogenesis. Blood 111:
1182–1192.
34. Chhabra A, Fernando H, Watkins G, Mansel RE, Jiang WG (2007) Expression
of transcription factor CREB1 in human breast cancer and its correlation with
prognosis. Oncol Rep 18: 953–958.
35. Linnerth NM, Greenaway JB, Petrik JJ, Moorehead RA (2008) cAMP response
element-binding protein is expressed at high levels in human ovarian
adenocarcinoma and regulates ovarian tumor cell proliferation. Int J Gynecol
Cancer 18: 1248–1257.
36. Sakamoto KM, Frank DA (2009) CREB in the pathophysiology of cancer:
implications for targeting transcription factors for cancer therapy. Clin Cancer
Res 15: 2583–2587.
37. Xiao X, Li BX, Mitton B, Ikeda A, Sakamoto KM (2010) Targeting CREB for
cancer therapy: friend or foe. Curr Cancer Drug Targets 10: 384–391.
38. Zhang X, Odom DT, Koo SH, Conkright MD, Canettieri G, et al. (2005)
Genome-wide analysis of cAMP-response element binding protein occupancy,
phosphorylation, and target gene activation in human tissues. Proc Natl Acad
Sci U S A 102: 4459–4464.
39. Yang WS, Stockwell BR (2008) Inhibition of casein kinase 1-epsilon induces
cancer-cell-selective, PERIOD2-dependent growth arrest. Genome Biol 9: R92.
40. Lu D, Zhao Y, Tawatao R, Cottam HB, Sen M, et al. (2004) Activation of the
Wnt signaling pathway in chronic lymphocytic leukemia. Proc Natl Acad
Sci U S A 101: 3118–3123.
41. Pukrop T, Klemm F, Hagemann T, Gradl D, Schulz M, et al. (2006) Wnt 5a
signaling is critical for macrophage-induced invasion of breast cancer cell lines.
Proc Natl Acad Sci U S A 103: 5454–5459.
42. Iozzo RV, Eichstetter I, Danielson KG (1995) Aberrant expression of the growth
factor Wnt-5A in human malignancy. Cancer Res 55: 3495–3499.
43. Lejeune S, Huguet EL, Hamby A, Poulsom R, Harris AL (1995) Wnt5a cloning,
expression, and up-regulation in human primary breast cancers. Clin Cancer
Res 1: 215–222.
44. Sun CX, Young HW, Molina JG, Volmer JB, Schnermann J, et al. (2005) A
protective role for the A1 adenosine receptor in adenosine-dependent
pulmonary injury. J Clin Invest 115: 35–43.
45. Rice BW, Cable MD, Nelson MB (2001) In vivo imaging of light-emitting
probes. J Biomed Opt 6: 432–440.
ROR1 Can Contribute to Breast Cancer Cell Growth
PLoS ONE | www.plosone.org 12 March 2012 | Volume 7 | Issue 3 | e31127
